Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Biomx stock price, quote, forecast and news

PHGE
US09090D1037
A2P9A0

Price

1.06
Today +/-
-0.01
Today %
-1.41 %
P

Biomx stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biomx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biomx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biomx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biomx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biomx Stock Price History

DateBiomx Price
9/27/20241.06 undefined
9/26/20241.07 undefined
9/25/20241.07 undefined
9/24/20241.14 undefined
9/23/20241.09 undefined
9/20/20241.02 undefined
9/19/20241.06 undefined
9/18/20241.03 undefined
9/17/20241.02 undefined
9/16/20240.99 undefined
9/13/20240.99 undefined
9/12/20241.04 undefined
9/11/20240.99 undefined
9/10/20241.08 undefined
9/9/20241.13 undefined
9/6/20241.19 undefined
9/5/20241.20 undefined
9/4/20241.15 undefined
9/3/20241.13 undefined
8/30/20241.22 undefined

Biomx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biomx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biomx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biomx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biomx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biomx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biomx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biomx’s growth potential.

Biomx Revenue, EBIT and net profit per share

DateBiomx RevenueBiomx EBITBiomx Net Income
2029e43.14 M undefined0 undefined-6.66 M undefined
2028e4.69 M undefined-55.25 M undefined-5.29 M undefined
2027e0 undefined-56.24 M undefined-5.84 M undefined
2026e0 undefined-47.26 M undefined-4.2 M undefined
2025e0 undefined-36.31 M undefined-4.08 M undefined
2024e0 undefined-31.14 M undefined-4.2 M undefined
20230 undefined-25.35 M undefined-26.17 M undefined
20220 undefined-27.22 M undefined-28.32 M undefined
20210 undefined-35.46 M undefined-36.23 M undefined
20200 undefined-30.26 M undefined-30.09 M undefined
20190 undefined-22.21 M undefined-20.56 M undefined
20180 undefined-400,000 undefined350,000 undefined
20170 undefined0 undefined0 undefined

Biomx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000443
------------975.00
-------------
0000000000000
00-22-30-35-27-25-31-36-47-56-550
------------1,375.00-
00-20-30-36-28-26-4-4-4-5-5-6
---50.0020.00-22.22-7.14-84.62--25.00-20.00
1.7525.6223.0626.0129.8551.33000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Biomx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biomx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
00.782.2656.3362.133.3314.91
0000000
0000000
0000000
00.042.224.344.543.552.15
00.7484.4860.6766.6436.8817.06
003.036.669.838.657.4
070.8800000
0000000
004.563.041.5200
0000000
600100000
0.0670.887.69.711.358.657.4
0.0671.6292.0870.3777.9945.5324.46
             
065.7500000
0.024.65126.63129.73156.02157.84166.05
0350-42,170-72,260-108,480-136,800-162,970
0000000
0000000
0.0270.7584.4657.4747.5421.043.08
00.233.252.322.80.821.38
000.961.993.091.571.96
0.040.142.012.855.161.262.06
0000000
000004.285.79
0.040.376.227.1611.057.9311.18
000014.4110.595.4
0000000
00.51.445.7355.965.37
00.51.445.7319.4116.5510.77
0.040.877.6612.8930.4624.4821.95
0.0671.6292.1270.367845.5225.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biomx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biomx's financial health and stability.

Assets

Biomx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biomx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biomx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biomx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20172018null2019202020212022
000-20-30-36-28
0000222
0000000
000203-4
0000321
0000001,000
0000000
000-17-24-27-29
000-1-1-30
0-70-7019-1016-2
0-70-7021-919-2
0000000
00000140
0707010230
07070610370
00059000
0000000
00063-3525-30
0-0.20-18.89-25.46-31.25-29.2
0000000

Biomx stock margins

The Biomx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biomx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biomx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biomx's sales revenue. A higher gross margin percentage indicates that the Biomx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biomx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biomx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biomx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biomx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biomx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biomx Margin History

Biomx Gross marginBiomx Profit marginBiomx EBIT marginBiomx Profit margin
2029e0 %0 %-15.45 %
2028e0 %-1,177.52 %-112.85 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Biomx Stock Sales Revenue, EBIT, Earnings per Share

The Biomx earnings per share therefore indicates how much revenue Biomx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biomx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biomx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biomx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biomx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biomx Revenue, EBIT and net profit per share

DateBiomx Sales per ShareBiomx EBIT per shareBiomx Earnings per Share
2029e2.41 undefined0 undefined-0.37 undefined
2028e0.26 undefined0 undefined-0.3 undefined
2027e0 undefined0 undefined-0.33 undefined
2026e0 undefined0 undefined-0.23 undefined
2025e0 undefined0 undefined-0.23 undefined
2024e0 undefined0 undefined-0.23 undefined
20230 undefined-0.49 undefined-0.51 undefined
20220 undefined-0.91 undefined-0.95 undefined
20210 undefined-1.36 undefined-1.39 undefined
20200 undefined-1.31 undefined-1.3 undefined
20190 undefined-3.95 undefined-3.66 undefined
20180 undefined-0.2 undefined0.18 undefined
20170 undefined0 undefined0 undefined

Biomx business model

Biomx Inc is a biotech company specializing in the development of bacterial therapies for the treatment of neurological and metabolic disorders. The company was founded in 2015 in Israel and has since moved its headquarters to San Francisco. Biomx's business model is based on the discovery, isolation, and characterization of bacterial strains associated with specific diseases, and the development of therapies that can target and eliminate these bacteria. The company employs a combination of cutting-edge genomic, proteomic, and bioinformatic technologies to identify and analyze new bacterial species and strains. Biomx has two main areas of focus. The first is the development of bacteriophages (viruses that infect and destroy bacteria) that specifically target certain bacterial species associated with particular diseases. This includes the Colorectal Cancer program, which aims to develop bacterial therapies for the treatment of colon cancer. The second area is the development of bacterial therapies targeting specific pathogens. One potential therapy that could be developed in the future, for example, is one that targets the bacterium Helicobacter pylori, which can cause stomach ulcers and stomach cancer. Biomx has also formed partnerships with other leading biopharmaceutical companies to utilize its technology platforms and develop bacterial therapies. Biomx has several promising products in its pipeline, including BX002, a bacteriophage product for the treatment of acute diarrhea caused by Clostridium difficile, CX002, a bacterial product for the treatment of acute respiratory failure, and a program for the development of bacterial therapies for the treatment of Crohn's disease. Overall, Biomx has played a significant role in the development of new methods for disease treatment in recent years and is expected to continue to be a key player in the biotechnology industry in the future. Biomx is one of the most popular companies on Eulerpool.com.

Biomx SWOT Analysis

Strengths

Biomx Inc has developed cutting-edge technology in the field of microbiome therapeutics. This advanced technology gives the company a competitive advantage and positions them as a leader in the industry.

Biomx Inc has a dedicated team of highly skilled researchers and scientists who are focused on developing innovative microbiome-based therapies. Their strong R&D capabilities enable them to create novel treatments and stay at the forefront of the industry.

Weaknesses

Biomx Inc heavily relies on external funding to support its research and development activities. This dependence on outside investment creates a vulnerability and potential risk if funding sources become limited or unavailable.

Currently, Biomx Inc has a limited product portfolio with only a few microbiome-based therapies in development. This lack of diversification may limit their revenue streams and leave them exposed to market fluctuations or competition.

Opportunities

The increasing awareness about the importance of the microbiome in human health has created a growing demand for microbiome therapeutics. Biomx Inc can capitalize on this opportunity by expanding its product offerings and capturing a larger market share.

Biomx Inc can explore collaborations and partnerships with other pharmaceutical companies or research institutions to leverage their expertise, resources, and reach. Such collaborations can accelerate their research efforts and enhance their market presence.

Threats

The microbiome therapeutics industry is subject to various regulatory approvals and compliance requirements. Any delays or obstacles in obtaining necessary approvals or adhering to regulatory standards could hinder Biomx Inc's product development and commercialization efforts.

Biomx Inc faces significant competition from established pharmaceutical companies that have their own microbiome research programs. These companies may have greater financial resources, well-established networks, and a competitive edge, posing a challenge to Biomx Inc's market position.

Biomx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biomx historical P/E ratio, EBIT, and P/S ratio.

Biomx shares outstanding

The number of shares was Biomx in 2023 — This indicates how many shares 51.33 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biomx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biomx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biomx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biomx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biomx Stock splits

In Biomx's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Biomx.

Biomx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.88 -0.7  (20.81 %)2024 Q2
3/31/2024-1.17 -1.5  (-27.88 %)2024 Q1
12/31/2023-0.11 -0.08  (28.7 %)2023 Q4
9/30/2023-0.1 -0.13  (-27.45 %)2023 Q3
6/30/2023-0.15 -0.12  (18.86 %)2023 Q2
3/31/2023-0.18 -0.2  (-12.04 %)2023 Q1
12/31/2022-0.23 -0.19  (19.01 %)2022 Q4
9/30/2022-0.23 -0.23  (0.9 %)2022 Q3
6/30/2022-0.28 -0.25  (9.22 %)2022 Q2
3/31/2022-0.3 -0.27  (9.76 %)2022 Q1
1
2

Biomx list of shareholders

%
Name
Stocks
Change
Date
6.06811 % 8VC GP I, LLC1,086,1911,086,19112/31/2023
5.15531 % Ugwumba (Chidozie)922,800-2,074,22512/31/2022
34.13463 % Deerfield Management Company, L.P.6,110,0986,110,0983/15/2024
25.43193 % Cystic Fibrosis Foundation4,552,31502/29/2024
25.41899 % Nimble Ventures LLC4,550,00003/28/2024
25.23793 % OrbiMed Advisors, LLC4,517,58903/19/2024
17.06631 % AMR Action Fund LP3,054,8703,054,8703/15/2024
15.86432 % Telmina Ltd2,839,71403/28/2024
11.91845 % Johnson & Johnson Innovation-JJDC, Inc.2,133,402012/31/2023
0.61617 % Renaissance Technologies LLC110,294-34,33312/31/2023
1
2
3
4

Biomx Executives and Management Board

Mr. Jonathan Solomon46
Biomx Chief Executive Officer, Director (since 2019)
Compensation 1.04 M
Dr. Merav Bassan57
Biomx Chief Development Officer
Compensation 562,918
Mr. Assaf Oron48
Biomx Chief Business Officer
Compensation 496,213
Ms. Marina Wolfson39
Biomx Chief Financial Officer
Compensation 396,243
Dr. Russell Greig70
Biomx Independent Chairman of the Board
Compensation 197,385
1
2
3

Most common questions regarding Biomx

What values and corporate philosophy does Biomx represent?

Biomx Inc represents a strong commitment to innovation, research, and breakthroughs in the field of microbiome therapeutics. The company's corporate philosophy is centered around developing personalized treatments to address unmet medical needs related to serious diseases and conditions caused by dysbiosis within the human microbiome. Biomx Inc strives to harness the power of the microbiome to improve patient outcomes and quality of life. Through cutting-edge technologies and strategic partnerships, Biomx Inc aims to advance the understanding and utilization of the microbiome, paving the way for innovative therapeutic solutions.

In which countries and regions is Biomx primarily present?

Biomx Inc is primarily present in the United States, with headquarters located in Ness Ziona, Israel.

What significant milestones has the company Biomx achieved?

Biomx Inc has achieved several significant milestones. The company has successfully developed a unique and innovative biotechnology platform that focuses on engineered phage products for the treatment of various diseases. Biomx Inc has also formed strategic partnerships with leading pharmaceutical companies, further enhancing their research and development capabilities. Notably, the company has advanced its clinical programs and successfully initiated Phase 1b/2a clinical studies, demonstrating promising results. Additionally, Biomx Inc has raised substantial funding through successful financing rounds, enabling them to support their cutting-edge research and reach key developmental targets. These achievements highlight Biomx Inc's commitment to advancing its novel therapeutic solutions and positioning itself as a key player in the biotechnology industry.

What is the history and background of the company Biomx?

Biomx Inc is a biotechnology company specializing in the development of novel therapeutics using customized phage-based microbiome engineering. Founded in 2015, Biomx is dedicated to harnessing the power of the human microbiome to treat various diseases. With a focus on inflammatory bowel disease (IBD) and cancer, Biomx aims to revolutionize the field of microbiome-based therapeutics. Through their proprietary platform, Biomx engages in comprehensive research and development, leveraging cutting-edge technologies and scientific expertise. By understanding the intricate relationship between the human microbiome and diseases, Biomx is committed to delivering innovative, personalized therapies that have the potential to transform patient outcomes and improve lives.

Who are the main competitors of Biomx in the market?

The main competitors of Biomx Inc in the market include companies like Vedanta Biosciences, Seres Therapeutics, and Second Genome.

In which industries is Biomx primarily active?

Biomx Inc is primarily active in the field of microbiome-based therapeutics.

What is the business model of Biomx?

Biomx Inc operates with a business model focused on the development of novel therapeutics using its proprietary microbiome-based technology platform. The company utilizes advanced computational tools and synthetic biology to identify and modify specific bacterial strains within the human microbiome, aiming to treat various diseases. By leveraging the potential of bacteria living within the body, Biomx Inc seeks to offer innovative solutions for conditions such as inflammatory bowel disease (IBD), cancer, and immuno-oncology. Through targeted modifications and interventions, Biomx Inc aims to harness the power of the microbiome to improve human health and address unmet medical needs.

What is the P/E ratio of Biomx 2024?

The Biomx P/E ratio is -12.9.

What is the P/S ratio of Biomx 2024?

The Biomx P/S ratio is 0.

What is the AlleAktien quality score of Biomx?

The AlleAktien quality score for Biomx is 1/10.

What is the revenue of Biomx 2024?

The revenue cannot currently be calculated for Biomx.

How high is the profit of Biomx 2024?

The expected Biomx profit is -4.2 M USD.

What is the business model of Biomx

The company Biomx Inc is a biotechnology company that specializes in the development and application of microbiome-related therapies. The various divisions of the company include research, development, and marketing of bacterial therapies and diagnostic tools for various diseases such as chronic inflammatory bowel disease, cancer, and skin diseases.

What is the Biomx dividend?

Biomx pays a dividend of 0 USD distributed over payouts per year.

How often does Biomx pay dividends?

The dividend cannot currently be calculated for Biomx or the company does not pay out a dividend.

What is the Biomx ISIN?

The ISIN of Biomx is US09090D1037.

What is the Biomx WKN?

The WKN of Biomx is A2P9A0.

What is the Biomx ticker?

The ticker of Biomx is PHGE.

How much dividend does Biomx pay?

Over the past 12 months, Biomx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biomx is expected to pay a dividend of 0 USD.

What is the dividend yield of Biomx?

The current dividend yield of Biomx is .

When does Biomx pay dividends?

Biomx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biomx?

Biomx paid dividends every year for the past 0 years.

What is the dividend of Biomx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biomx located?

Biomx is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biomx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biomx from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Biomx pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Biomx in the year 2023?

In the year 2023, Biomx distributed 0 USD as dividends.

In which currency does Biomx pay out the dividend?

The dividends of Biomx are distributed in USD.

All fundamentals about Biomx

Our stock analysis for Biomx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.